ATE424825T1 - Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten - Google Patents

Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten

Info

Publication number
ATE424825T1
ATE424825T1 AT02756536T AT02756536T ATE424825T1 AT E424825 T1 ATE424825 T1 AT E424825T1 AT 02756536 T AT02756536 T AT 02756536T AT 02756536 T AT02756536 T AT 02756536T AT E424825 T1 ATE424825 T1 AT E424825T1
Authority
AT
Austria
Prior art keywords
attention deficit
treatment
hyperactivity disorders
hyperactivity
disorders
Prior art date
Application number
AT02756536T
Other languages
English (en)
Inventor
Daniela Brunner
Daniel Goodman
Original Assignee
Psychogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psychogenics Inc filed Critical Psychogenics Inc
Application granted granted Critical
Publication of ATE424825T1 publication Critical patent/ATE424825T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02756536T 2001-07-20 2002-07-19 Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten ATE424825T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30682501P 2001-07-20 2001-07-20
US38293102P 2002-05-23 2002-05-23

Publications (1)

Publication Number Publication Date
ATE424825T1 true ATE424825T1 (de) 2009-03-15

Family

ID=26975388

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02756536T ATE424825T1 (de) 2001-07-20 2002-07-19 Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten

Country Status (10)

Country Link
US (5) US7504395B2 (de)
EP (2) EP2036547A3 (de)
JP (1) JP5080716B2 (de)
AT (1) ATE424825T1 (de)
AU (2) AU2002322539B2 (de)
CA (1) CA2453837C (de)
DE (1) DE60231507D1 (de)
DK (1) DK1408976T5 (de)
ES (1) ES2323451T7 (de)
WO (1) WO2003007956A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US8751031B2 (en) * 2004-02-06 2014-06-10 Zircore, Llc System and method for mass custom manufacturing of dental crowns and crown components
JP2009500425A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
ES2675544T3 (es) 2008-05-30 2018-07-11 Psychogenics Inc. Tratamiento para trastornos mentales y neurológicos
JP2012526832A (ja) * 2009-05-13 2012-11-01 スノビオン プハルマセウトイカルス インコーポレイテッド トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用
CN102481291B (zh) * 2009-06-25 2015-10-21 阿尔考布拉有限公司 用于治疗、减轻症状、缓解、改善和预防认知疾病、障碍或病症的方法
WO2011000564A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of drug addiction
EP2448579A1 (de) 2009-06-30 2012-05-09 Merz Pharma GmbH & Co. KGaA Eltoprazin zur behandlung von gewichtsstörungen
US20120136005A1 (en) 2009-06-30 2012-05-31 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of anxiety
WO2011000562A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of certain movement disorders
US8469711B2 (en) * 2009-09-29 2013-06-25 Advanced Training System Llc System, method and apparatus for driver training of shifting
WO2014180556A1 (en) * 2013-05-06 2014-11-13 Merz Pharma Gmbh & Co. Kgaa Arylpiperazines
JP7406285B1 (ja) 2023-03-09 2023-12-27 国立大学法人島根大学 ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンｕｄｐ－グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
CH653021A5 (fr) 1981-04-24 1985-12-13 Delalande Sa Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
FR2524312B1 (fr) * 1982-04-01 1985-10-04 Tech Cuir Centre Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
AU577802B2 (en) 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
EP0189612B1 (de) 1984-12-21 1992-11-04 Duphar International Research B.V Arzneimittel mit psychotroper Wirkung
EP0190472B1 (de) 1984-12-21 1989-07-12 Duphar International Research B.V Arzneimittel mit antipsychotischer Wirkung
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4797286A (en) * 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
DE3782525T2 (de) 1986-02-27 1993-05-27 Duphar Int Res Aryl-substituierte(n-piperidinyl)methyl und (n-piperazinyl)methylazole mit antipsychotischer wirkung.
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
IE74200B1 (en) 1987-09-11 1997-07-16 Duphar Int Res Anxiolytically active piperazine derivatives
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
IL92544A0 (en) 1988-12-08 1990-08-31 Duphar Int Res Piperazine derivatives,their preparation and pharmaceutical compositions containing them
GB8830312D0 (en) 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
SE8904361D0 (sv) 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
FR2670491B1 (fr) 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
IT1251144B (it) 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9125900D0 (en) 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
EP0556889A1 (de) 1992-02-18 1993-08-25 Duphar International Research B.V Verfahren zur Herstellung von Aryl(Homo)Piperazine
FR2692264B1 (fr) 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
EP0939135A1 (de) 1992-12-21 1999-09-01 Duphar International Research B.V Wesentlich saubere hetero-bicyclische Alkohol-Enantiomeren
RU2118322C1 (ru) 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
WO1995003801A1 (en) * 1993-07-28 1995-02-09 Nippon Shinyaku Co., Ltd. Antidepressant
WO1995011243A1 (en) 1993-10-19 1995-04-27 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
EP0650964A1 (de) 1993-11-02 1995-05-03 Duphar International Research B.V 1- 2H-1-Benzopyran-2-on-8-yl -Piperazin Derivate
IL112764A0 (en) 1994-03-18 1995-05-26 Ferrer Int New chromene derivatives
FI965238L (fi) 1994-06-29 1996-12-27 Pfizer Aryyli- ja heteroaryylialkoksinaftaleenijohdannaiset
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
EP0710481A1 (de) 1994-11-02 1996-05-08 Duphar International Research B.V Verwendung von Flesinoxan zur Wahrnehmungssteigerung
WO1996017831A1 (de) 1994-12-07 1996-06-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Uracilderivate
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US6114334A (en) 1995-07-13 2000-09-05 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
WO1997007120A1 (en) 1995-08-11 1997-02-27 Smithkline Beecham Plc Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
JP3989554B2 (ja) 1996-03-29 2007-10-10 デユフアー・インターナシヨナル・リサーチ・ベー・ブイ ピペラジンおよびピペリジン化合物
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
DK0932609T3 (da) 1996-10-15 2003-09-01 Wyeth Corp Azaheterocyclomethylderivater af 2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-on
JPH10269708A (ja) 1997-03-25 1998-10-09 Hiroshi Fukuda 多信号用メモリーシステム
FR2760014B1 (fr) 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
KR100545329B1 (ko) 1997-07-25 2006-01-24 하. 룬트벡 아크티에 셀스카브 인돌 및 2,3-디히드로인돌 유도체, 그들의 제조방법 및 사용
US5942244A (en) * 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
SE9703376D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
FR2769312B1 (fr) 1997-10-03 1999-12-03 Adir Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6387904B2 (en) 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
ATE247963T1 (de) 1998-05-26 2003-09-15 Pfizer Prod Inc Medikament zur behandlung von glaukoma und ischämischer retinopathie
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
WO1999065887A1 (en) 1998-06-15 1999-12-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
US6242448B1 (en) 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
ES2219302T3 (es) 1999-01-07 2004-12-01 Wyeth Derivados de arilpiperazinil-ciclohexilindol para el tratamiento de la depresion.
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
US6306859B1 (en) 1999-03-02 2001-10-23 American Home Products Corporation N-substituted imide derivatives with serotonergic activity
ES2162731B1 (es) 1999-06-04 2003-02-16 Faes Fabrica Espanola De Produ Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas.
EP1204654B1 (de) 1999-07-29 2003-07-23 Eli Lilly And Company Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
ES2198329T3 (es) 1999-07-29 2004-02-01 Eli Lilly And Company Agonistas de la serotonina benzofurilpiperazina.
WO2001014330A2 (en) 1999-08-23 2001-03-01 Solvay Pharmaceuticals B.V. Phenylpiperazines as serotonin reuptake inhibitors
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
EP1283838B1 (de) 2000-05-12 2003-12-03 Solvay Pharmaceuticals B.V. Piperazin- und piperidinverbindungen
US20030186838A1 (en) 2000-05-12 2003-10-02 Feenstra Roelof W. Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
US20020016334A1 (en) 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
DE10041574A1 (de) 2000-08-24 2002-03-07 Merck Patent Gmbh Chromenonderivate
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
JP4184077B2 (ja) * 2000-11-02 2008-11-19 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしての１−アリールまたは１−アルキルスルホニル−ヘテロシクリルベンザゾール
US6469007B2 (en) 2000-11-28 2002-10-22 Wyeth Serotonergic agents
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
MXPA03011769A (es) 2001-06-29 2004-04-02 Lundbeck & Co As H Derivados de heteroarilo novedosos, su preparacion y uso.
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
HU227237B1 (en) 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
ITMI20012060A1 (it) 2001-10-05 2003-04-05 Recordati Chem Pharm Nuovi eterocilcli n-acilati
EP1336406A1 (de) 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partieller Dopamin-D2 Rezeptoragonist plus Substanzen mit Serotonin- und/oder Noradrenalin inhibitorischer Aktivität
WO2003074518A1 (en) 2002-03-06 2003-09-12 Merck Patent Gmbh Thiazole derivatives and their use d2- and 5-ht1a-receptor ligands
ES2329122T3 (es) 2002-03-12 2009-11-23 Wyeth Procedimiento para sintetizar n-aril piperazinas quirales.
JP4397693B2 (ja) 2002-03-12 2010-01-13 ワイス Ｎ１−（２’−ピリジル）−１，２−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用
BR0308347A (pt) 2002-03-12 2005-01-25 Wyeth Corp Processo para fabricação de piperazinas 1,4-dissubstituìdas quirais
PT1506179E (pt) 2002-05-13 2006-06-30 Hoffmann La Roche Derivados de benzoxazina como moduladores de 5-ht6 e suas utilizacoes
US20040072839A1 (en) 2002-06-14 2004-04-15 Amedeo Leonardi 1-Phenylalkylpiperazines
US20040002500A1 (en) 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US7067518B2 (en) 2002-09-05 2006-06-27 Wyeth Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents
US7153849B2 (en) 2002-09-12 2006-12-26 Wyeth Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans
PL377770A1 (pl) 2002-11-08 2006-02-20 F. Hoffmann-La Roche Ag Podstawione benzoksazynony i ich zastosowanie
HU227592B1 (en) 2002-11-13 2011-09-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Use of substituted alkyl-piridazinone derivatives for the treatment of memory decline and learning malfunctions
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
DE10259244A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
US20050004105A1 (en) 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
KR100751604B1 (ko) 2003-03-03 2007-08-22 에프. 호프만-라 로슈 아게 5-ｈｔ6 조절자로서 사용되는 2,5- 및 2,6-치환된테트라하이드로아이소퀴놀린
MXPA05012320A (es) 2003-05-16 2006-01-30 Pfizer Prod Inc Tratamientos de trastornos bipolares y sintomas asociados.
CA2525868A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
EP1633360A1 (de) 2003-05-16 2006-03-15 Pfizer Products Incorporated Behandlung von psychotischen und depressiven erkrankungen
MXPA05012325A (es) 2003-05-16 2006-01-30 Pfizer Prod Inc Procedimiento para potenciar la cognicion usando zipirasidona.
US20050065158A1 (en) 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
ATE371653T1 (de) 2003-12-09 2007-09-15 Hoffmann La Roche Benzoxazinderivate und deren verwendungen
WO2005063296A2 (en) 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders

Also Published As

Publication number Publication date
US20030050308A1 (en) 2003-03-13
EP1408976B1 (de) 2009-03-11
US20060004023A1 (en) 2006-01-05
ES2323451T3 (es) 2009-07-16
AU2007254677B2 (en) 2009-11-12
EP2036547A2 (de) 2009-03-18
WO2003007956A1 (en) 2003-01-30
JP2004538282A (ja) 2004-12-24
AU2007254677A1 (en) 2008-01-24
ES2323451T7 (es) 2011-08-01
JP5080716B2 (ja) 2012-11-21
DE60231507D1 (de) 2010-07-01
EP2036547A3 (de) 2009-12-23
HK1065478A1 (en) 2005-02-25
EP1408976A4 (de) 2007-05-16
DK1408976T5 (da) 2011-01-10
US7557109B2 (en) 2009-07-07
EP1408976A1 (de) 2004-04-21
US7504395B2 (en) 2009-03-17
CA2453837C (en) 2011-10-04
US20120070494A1 (en) 2012-03-22
US20110008425A1 (en) 2011-01-13
EP1408976B3 (de) 2010-08-25
US20090104261A1 (en) 2009-04-23
AU2002322539B2 (en) 2007-09-27
DK1408976T3 (da) 2009-06-29
CA2453837A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
ATE424825T1 (de) Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
ATE514430T1 (de) Behandlung des alpha-galactosidase a mangels
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
DE69534130D1 (de) Verbindungen zur behandlung von erkrankungen,die mit des vasculogenese und/oder angiogenese in verbunden stehen.
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE415968T1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
ATE420866T1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
ATE316787T1 (de) Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion
CY1109238T1 (el) Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη
ATE269078T1 (de) Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
DE60322075D1 (de) Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
ATE556707T1 (de) Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
ATE359783T1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties